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Letters to the EditorDiminished airway macrophage
expression of the Axl receptor
tyrosine kinase is associated with
defective efferocytosis in asthmaTo the Editor:
Up to 15% of the 300 million people affected by asthma
worldwide suffer from disease refractory to available medications
and associated with significant morbidity, particularly due to
frequent exacerbations secondary to respiratory viral infections.
Airwaymacrophages from patients with severe asthma are known
to be defective in apoptotic cell clearance.1-3 Because phagocy-
tosis of apoptotic cells, called efferocytosis, prevents secondary
necrosis and the release of proinflammatory necrotic cell debris,
defects in apoptotic cell uptake contribute to perpetuation of
lung inflammation.4 Although several processes have been impli-
cated in impaired efferocytosis in asthma, the underlying mecha-
nisms and the links between apoptotic cell clearance, respiratory
infections, and disease exacerbations remain unknown.
TAM (Tyro3, Axl, MerTK) receptor tyrosine kinases mediate
apoptotic cell uptake by phagocytes through the bridging
molecules Protein S or growth arrest specific 6 (Gas6), and are
critical for lung immune homeostasis.4We and others have shown
that Axl is specifically expressed on mouse airway macrophages,
is constitutively bound to its ligand Gas6, and is critical for effi-
cient efferocytosis.5,6 Axl-deficient mice develop exaggerated
lung inflammation upon influenza infection associated with accu-
mulation of apoptotic cells in the airways,5 indicating a critical
role for Axl in apoptotic cell clearance from the inflamed lung.
Here, we sought to define the TAM receptor expression profile
in human airway macrophages, characterize the local factors
driving their expression, and identify potential defects in TAM re-
ceptors contributing to defective efferocytosis in asthma.
We first performed mRNA expression profiling of TAM
receptors in peripheral blood monocytes, monocyte-derived
macrophages (MDMs), and airway macrophages isolated from
sputum samples obtained from 12 healthy donors (HDs) (for
details of experimental procedures and study cohort characteris-
tics, see this article’s Online Repository at www.jacionline.org).
TAM receptors displayed a strong cell type–specific expression
pattern: MerTK was preferentially expressed in MDMs, but not
monocytes or airway macrophages, whereas Axl expression
was restricted to airway macrophages (Fig 1, A). Using macro-
phages from the healthy margins of lung resections (which
contain both airway and alveolar macrophages), we confirmed
that only airway/alveolar macrophages constitutively expressed
high levels of Axl protein, while MDMs were strongly MerTK-
dominant (Fig 1, B and C). Apoptotic cell recognition by Axl re-
quires the bridgingmolecule Gas6 and, similar to mouse models,5
we detected Gas6 on most airway/alveolar macrophages (see Fig
E1 in this article’s Online Repository at www.jacionline.org).
These data reveal selectiveAxl expression on human airway/alve-
olar macrophages and constitutive binding of Gas6 rendering
these cells primed for apoptotic cell recognition through Axl. 2017 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1144We next investigated why Axl is exclusively expressed on
airway/alveolar macrophages. Axl mRNA and protein expression
was significantly reduced during ex vivo culture of HD airway/
alveolar macrophages from lung resections (Fig 1,D and E), sug-
gesting that these cells may require the airway microenvironment
to maintain their unique TAM receptor expression profile. To
identify factors that drive Axl expression, we stimulated
airway/alveolar macrophages with factors known to affect their
activation during infection and chronic inflammation. Strikingly,
only IFNs significantly restored Axl mRNA expression during
ex vivo culture (Fig 1, F). Restoration of Axl expression by
IFNs, in particular IFN-a and IFN-l, was also evident at the pro-
tein level (Fig 1, G). These findings indicate that homeostatic
levels of IFNs or their sustained production by bronchial epithe-
lial cells following previous viral infections drive selective Axl
expression and regulate the efferocytic function of human
airway/alveolar macrophages.
Previous studies have shown clear defects in efferocytosis in
severe asthma.1-3 On the basis of our observations, we hypothe-
sized that alterations in Axl may explain these defects. The extra-
cellular domain of Axl is cleaved upon engagement, and
alterations in soluble Axl (sAxl) levels have been reported in in-
flammatory conditions.7We compared the levels of sAxl in serum
and sputum from HDs and patients with moderate-to-severe
asthma (British Thoracic Society steps 3-5). Although no differ-
ence in sAxl was detected in serum samples between the 2 groups
(Fig 2, A), the levels of sAxl in sputum samples were significantly
elevated in patients with asthma compared with controls (Fig 2,
B), suggesting increased Axl shedding at the site of inflammation.
Next, we compared Axl and MerTK mRNA expression in
peripheral blood monocytes, MDMs, and airway macrophages in
sputum from patients with moderate-to-severe asthma and HDs.
Similar levels of MerTK were expressed in both groups in all
analyzed cell types (Fig 2,C), whereas Axl expression was signif-
icantly reduced in airwaymacrophages from patients with asthma
(P < .001). The observed difference was restricted to the site of
inflammation as monocytes and MDMs from asthma patients
and HDs expressed comparable, albeit low, levels of Axl (Fig 2,
D). To test the functional significance of reduced Axl expression
in asthma, we determined the amounts of DNA-histone com-
plexes (nucleosomes), a hallmark of necrosis and secondary ne-
crosis of apoptotic cells,5 in the airways of the same patients.
Extracellular nucleosome levels were elevated in sputum from pa-
tients withmoderate-to-severe asthma compared with HDs (Fig 2,
E), and negatively correlated with airway macrophage Axl
expression (Fig 2, F; R 5 20.71; P < .0001). These results indi-
cate that Axl is the main apoptotic cell recognition receptor ex-
pressed on human airway macrophages and reduced Axl
expression and/or increased shedding might perpetuate chronic
inflammation in asthma.
In conclusion, we report for the first time that (1) the apoptotic
cell recognition receptor Axl is exclusively expressed by human
airway/alveolar macrophages, (2) Axl expression depends on the
presence of type I/III IFNs, (3) increased shedding of sAxl occurs
in sputum from patients with moderate-to-severe asthma, and (4)
Axl mRNA expression in airway macrophages isolated from
sputum is reduced in patients with moderate-to-severe asthma.
These findings have important implications for those patients at
FIG 1. Axl is exclusively expressed on human airway/alveolar macrophages, is downregulated ex vivo and
restored by interferons. A, Relative Axl and MerTKmRNA expression in HDmonocytes (mono), MDMs, and
airway macrophages (AMF) (n5 12). B, Axl and MerTK protein expression in mono, MDMs, and AMF from
HDs (n 5 5). C, Immunoblotting of Axl, MerTK, and actin in MDMs (n 5 3) and AMF (n 5 4) from HDs. Axl
relative mRNA (n 5 7) (D) and protein expression in HD AMF at 0 hour and 24 hours in culture (E). F, Axl
relative mRNA expression in HD AMF at isolation (0 hour) and after 24-hour culture with or without M-
CSF, GM-CSF, IFN-g, IFN-a, IFN-l, IL-4, IL-10, or dexamethasone (n 5 5). G, Axl protein expression in
AMF at 0 hour and 24 hours in culture with or without IFN-g, IFN-a, or IFN-l (n 5 3). *P < .05, **P < .01,
and ***P < .001.
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particularly in light of recent reports demonstrating the role of
altered IFN responses during respiratory infections in asthma.8
Our results suggest that strategies aimed at restoring or activating
Axl could be beneficial in patients with asthma by facilitating
apoptotic cell clearance. This idea is supported by a recent clinical
trial where inhaled type I IFN prevented viral infection–induced
exacerbation of disease symptoms only in patients with severe
asthma.9 In light of our observation that IFNs restore Axl expres-
sion on airway macrophages, the beneficial effects of type I IFN
might be at least partly attributed to improved efferocytic function
and prevention of secondary necrosis. Collectively, data from this
study provide evidence that Axl is an important regulator of lung
immune homeostasis and identify a novel pathway that could be
targeted to improve defective efferocytosis in asthma.
We acknowledge the Manchester Allergy, Respiratory and Thoracic
Surgery Biobank and the North West Lung Centre Charity for supporting
this project. In addition, we thank the study participants for their contribution.
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nerve growth factor and attenu-
ates allergic inflammation in mite
allergen–induced allergic rhinitisTo the Editor:
Allergic rhinitis (AR), which affects approximately 10% to
15% of the population worldwide, is a chronic inflammatory
disease of the nasal mucosa involving nasal airway hyper-
responsiveness (AHR), an inappropriate activity of the nervous
METHODS
Study population and sample collection
Paired peripheral blood and sputum samples (spontaneous or induced by
using hypertonic saline) were collected from 15 healthy individuals and 46
patients with moderate-to-severe asthma fulfilling the British Thoracic
Society criteria (disease steps 3-5).E1 Clinical characteristics of patients are
presented in Table E1. For some experiments, marginal noncancerous lung tis-
suewas collected from patients undergoing surgery for suspected or confirmed
cancer (n 5 15). Patients included in this study did not have a history of any
chronic inflammatory lung disease and had normal lung function (median [in-
terquartile range] FEV1/forced vital capacity ratio, 0.74 [0.70-0.79]). All sam-
ples were collected at the University Hospital of South Manchester/North
West Lung Centre under the framework of the Manchester Allergy, Respira-
tory and Thoracic Surgery Biobank (study nos. M2014-17 and M2015-32)
with ethical approval of the National Research Ethics Service (REC reference
10/H1010/7). All patients provided written informed consent before participa-
tion in the study. Peripheral blood from healthy individuals (leukocyte cones)
was also obtained from the National Blood Transfusion Service (Manchester,
UK) with ethical approval by the University of Manchester ethics committee.
Cell isolation and culture
Lung tissue was perfused with PBS. The retrieved cell suspension was
centrifuged at 400g for 10 minutes, and the cell pellet was resuspended in
PBS and subjected to Ficoll-Paque (GE Healthcare, Buckinghamshire,
United Kingdom) density gradient centrifugation to remove granulocytes
and erythrocytes. The interface of mononuclear cells, containing predomi-
nantly airway/alveolar macrophages, was collected and washed in PBS,
and viable macrophages were counted using trypan blue exclusion and plated
at 1 3 106 cells/mL in RPMI 1640 supplemented with 10% FCS, 100 U/mL
penicillin, 100 mg/mL streptomycin, and 2 mM L-glutamine (complete me-
dium) for 1 hour at 378C for adherence. Nonadherent cells were removed
by extensive washing and airway/alveolar macrophages were either lysed
immediately or stimulated with M-CSF (50 ng/mL), GM-CSF (50 ng/mL),
IL-4 (20 ng/mL), IL-10 (20 ng/mL), IFN-g (50 ng/mL), IFN-l (100 ng/
mL) (all from Peprotech, Rocky Hill, NJ), IFN-a (1000 U/mL) (R&D Sys-
tems, Abingdon, United Kingdom), or dexamethasone (Dex, 1 mM)
(Sigma-Aldrich, Dorset, United Kingdom) for 24 hours. A 90% or more pu-
rity of airway macrophages was routinely achieved with this isolation
method.E2 To purify airway macrophages from sputum, samples were pro-
cessed as previously described.E3 Supernatants were stored at 2808C and
cells were incubated with 50 mg/mL DNase (Roche Diagnostics, Mannheim,
Germany) for 30 minutes at 378C, washed with PBS, and plated in 24-well
plates in complete medium. After 1-h adherence, cells were extensively
washed to remove nonadherent cells and airway macrophages were lysed
in RLT buffer (Qiagen, Manchester, United Kingdom) before RNA
extraction.
PBMCs were isolated by Ficoll-Paque density gradient centrifugation.
Monocytes were then purified by magnetic-activated cell sorting using human
CD14 MicroBeads (Miltenyi Biotec, Surrey, United Kingdom), plated at
5 3 105 cells/mL in complete medium containing 50 ng/mL M-CSF, and
cultured for 6 days before further processing.
RNA extraction and quantitative PCR
Total RNAwas isolated using RNeasymicro kit (Qiagen), quantified with a
Nanodrop spectrophotometer (Thermo Scientific, Waltham, Mass) and
equivalent amounts of RNA were reverse transcribed using High-Capacity
RNA-to-cDNA Kit (Life Technologies, Paisley, United Kingdom). Quantita-
tive PCR reactions were performed using TaqMan expression assays and
TaqMan Fast Universal PCR Master Mix on a QuantStudio 12K Flex PCR
system and the obtained data were analyzed using QuantStudio 12K Flex
Software (all from Life Technologies). Average expression of glyceraldehyde
3-phosphate dehydrogenase (GAPDH) and RPLP0 was used to calculate
relative mRNA expression of Axl and MerTK.
Immunoblotting and ELISA of cell lysates
Protein lysates were prepared in lysis buffer containing 1% Igepal CA-
630, 20 mM Tris, pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM EDTA, and
protease inhibitor cocktail (Sigma-Aldrich). Protein concentrations were
determined using a BCA Protein Assay Kit (Thermo Scientific) and
equivalent amounts of protein were resolved by electrophoresis on 4% to
15% mini-Protean TGX precast gels (BIO-RAD, Hercules, Calif). Proteins
were then transferred to nitrocellulosemembranes (BIO-RAD) using a semi-
dry Trans-Blot Turbo transfer system (BIO-RAD). Membranes were washed
in PBS containing 0.05% Tween-20 (Sigma-Aldrich) (PBS/T), blocked in
2% milk (BIO-RAD) in PBS/T, and incubated o/n at 48C with antibodies
recognizing MerTK (D21F11, Cell Signaling Technology, Beverly, Mass),
Axl (M20), or actin (I19-R) (both from Santa Cruz Biotechnology, Santa
Cruz, Calif) diluted in PBS/T containing 1% BSA. After washing in PBS/T,
membranes were incubated with horseradish peroxidase–conjugated anti-
rabbit, antimouse, or antigoat immunoglobulin antibodies (Dako, Cam-
bridge, United Kingdom), developed using a Clarity Western ECL Substrate
(BIO-RAD) and visualized with a ChemiDoc MP Imaging System (BIO-
RAD). Alternatively, Axl and MerTK protein levels were analyzed in cell
lysates using total Axl and MerTK ELISA kits (R&D Systems) as per the
manufacturer’s instructions and the data were presented as ng/mg total
protein in the lysate.
Flow cytometric analyses
Cells were stained with Zombie UV Flexible Viability dye (BioLegend,
SanDiego, Calif) for 20minutes followed by incubationwith HumanTruStain
FcX Fc receptor blocking solution (BioLegend) for 10 minutes. Cells were
then washed with FACS buffer (PBS containing 1% FCS and 2 mM EDTA)
and stained with PE/Cy7-conjugated anti-CD64 (clone 10.1, BioLegend) and
biotinylated anti-Gas6 (BAF885) or control biotinylated goat IgG (BAF108)
antibodies (all from R&D Systems) for 20 minutes at 48C. After washing with
FACS buffer, cells were incubated with BV421-conjugated streptavidin
(BioLegend) for 20 minutes at 48C, washed, and fixed by 10-min incubation
with 2% paraformaldehyde in PBS. Cells were acquired on a BD LSRFortessa
(BD Biosciences, San Jose, Calif) and data were analyzed using FlowJo
software (TreeStar, Ashland, Ore). Airway/alveolar macrophages were
defined as FSChiSSChiCD641 and highly autofluorescent. The strategy using
autofluorescence to define airway/alveolar macrophages was described
before.E4,E5
Detection of extracellular nucleosomes and soluble
Axl
Levels of nucleosomes in sputum samples were determined using the Cell
Death Detection ELISA Plus (Roche) according to the manufacturer’s
instructions.
To measure sAxl in serum samples, Maxisorp plates (Nunc, Roskilde,
Denmark) were coated o/n with 500 ng/mL goat anti-Axl antibody (AF154,
R&D Systems) in PBS. Plates were washed with wash buffer (50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 0.1% Tween-20) and blocked in 3% fish gelatin
(Norland Products Inc, Cranbury, NJ) diluted in wash buffer for 2 hours at
room temperature (RT). Serum was diluted 1:10 in blocking buffer and
incubated on the plates for 2 hours at 378C. After washing, plates were
incubated with polyclonal rabbit anti-Axl antibody (in-house, Ab042) diluted
in blocking buffer, followed by incubation with goat antirabbit horseradish
peroxidase conjugate (P0448, Dako) for 1 hour at RT. Plates were developed
using an OPD-substrate (Dako, S2045) and the absorbance was measured
using an Infinite 200 microplate reader (Tecan, M€annedorf, Switzerland).
To detect sAxl in sputum, samples from patients and controls (600 mL) or
an equal volume of standard solution containing 1, 5, or 10 ng/mL sAxl was
mixed with 1 mL PBS. sAxl standard was expressed and purified as
described previously.E6 The samples were precleared with 30 mL Protein G
sepharose (Life Technologies) for 30 minutes at 48C after which the beads
were removed by centrifugation at 2000g for 5 minutes. One microgram
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anti-Axl antibody (AF154, R&D Systems) was added together with 30 mL
Protein G sepharose to the supernatant and samples were incubated o/n at
48C under rotation. The beads were then washed twice with PBS and incu-
bated for 5 minutes in reducing Laemmli buffer at 958C. Supernatants
were separated on a 4% to 15% SDS-PAGE, transferred to a polyvinylidene
difluoride (PVDF) membrane, and probed against Axl (in-house, Ab042).
Blots were analyzed using the ImageLab software and the intensities of
the bands corresponding to sAxl were quantified. Normalization was per-
formed on each blot by setting the signal of the 5 ng/mL sAxl standard so-
lution IP reaction to 1. In all cases, samples from patients and controls
were run in parallel on each blot to minimize interblot variation.
Statistical analyses
Data are presented as mean 6 SEM (Fig 1, B, F, and G), as boxplots with
the line within the box denoting the median, boxes representing 25th and 75th
percentiles, and the lines outside the boxmarking theminimum andmaximum
values (Fig 2, A and B), or as symbols representing data from individual do-
nors. Nonparametric tests were used for comparisons between patient groups
or cell types and for in vitro studies of airway macrophages: Kruskal-Wallis
test followed by Dunn’s multiple comparison test (Fig 1, A and B), Wilcoxon
signed rank test (Fig 1, D), Friedman test followed by Dunn’s multiple com-
parison test (Fig 1, F), or Mann-Whitney U test (Fig 2, A-E). The Spearman
correlation coefficient was used for correlation analyses. P values of less
than .05 were considered statistically significant.
REFERENCES
E1. British Guideline on the Management of Asthma. Thorax 2008;63:iv1-121.
E2. Kent LM, Fox SM, Farrow SN, Singh D. The effects of dexamethasone on ciga-
rette smoke induced gene expression changes in COPD macrophages. Int Immu-
nopharmacol 2010;10:57-64.
E3. Pizzichini E, Pizzichini MM, Efthimiadis A, Hargreave FE, Dolovich J. Measure-
ment of inflammatory indices in induced sputum: effects of selection of sputum to
minimize salivary contamination. Eur Respir J 1996;9:1174-80.
E4. Baharom F, Thomas S, Rankin G, Lepzien R, Pourazar J, Behndig AF, et al. Den-
dritic cells and monocytes with distinct inflammatory responses reside in lung
mucosa of healthy humans. J Immunol 2016;196:4498-509.
E5. Desch AN, Gibbings SL, Goyal R, Kolde R, Bednarek J, Bruno T, et al.
Flow cytometric analysis of mononuclear phagocytes in nondiseased human
lung and lung-draining lymph nodes. Am J Respir Crit Care Med 2016;193:
614-26.
E6. Ekman C, Stenhoff J, Dahlback B. Gas6 is complexed to the soluble tyrosine ki-
nase receptor Axl in human blood. J Thromb Haemost 2010;8:838-44.
J ALLERGY CLIN IMMUNOL
OCTOBER 2017
1146.e2 LETTERS TO THE EDITOR
FIG E1. Gas6 is constitutively bound to the surface of human airway/alveolar macrophages (AMF). Flow
cytometric analysis of Gas6 on AMF isolated from healthy lung tissue. Live single cells were selected and
AMF were defined as FSChiSSChiCD451 (gates not shown) CD641 and highly autofluorescent. The histo-
gram of Gas6 surface expression is a representative of 3 analyzed donors. Solid line/open: Gas6 staining;
dotted line/shaded: isotype control. FSC-A, Forward scatter-area; SSC-H, side scatter-height.
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TABLE E1. Clinical features of patients with severe asthma and
healthy subjects included in the study
Feature
Moderate-to-severe
asthma (n 5 46)
Healthy
control (n 5 15)
Sex: male/female 19/27 4/11






BTS step 3 8
BTS step 4 12
BTS step 5 26
FEV1 (L) 2.14 (1.63-2.73) NA
FEV1 % predicted 77 (64-94) NA
FVC (L) 3.10 (2.63-3.69) NA
FVC % predicted 93 (83-109) NA
FEV1/FVC ratio 0.7 (0.59-0.79) NA
The values are expressed as counts or median (interquartile range).
BTS, British Thoracic Society; FVC, forced vital capacity; NA, not applicable/
available.
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